Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.19.3
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash flows used in operating activities:    
Net loss from continuing operations $ (13,587,512) $ (50,921,024)
Adjustments to reconcile net loss to net cash used in operations:    
Depreciation and amortization 1,263,844 1,715,321
Non-cash gain on derivative instruments (2,803)
Stock issued for services 477,933 161,003
Stock-based compensation 285,992 303,046
Non-cash interest expense 8,649,232
Amortization of debt discount 17,558,008 10,412,324
Non-cash settlement of debt (50,000)
Gain on extinguishment of debt (42,702,815)
Change in fair value of derivative instruments (13,696,214) 42,702,815
Value of convertible liabilities 12,435,250
Gain on purchase of Jamestown Medical Center (7,566,670)
Asset impairment 173,799
Gain on disposal of equipment under capital lease (551,155)
Loss from discontinued operations (434,843) (4,276,918)
Changes in operating assets and liabilities:    
Accounts receivable (2,840,437) 80,033
Prepaid expenses and other current assets 237,561 136,951
Inventory 234,194 (236,914)
Security deposits (94,143) (45,728)
Accounts payable and checks issued in excess of bank balance 4,076,972 1,674,969
Accrued expenses 6,416,725 1,245,165
Income tax assets and liabilities 738,827 546,752
Net cash used in operating activities of continuing operations (7,307,117) (18,173,341)
Net cash (used in) provided by operating activities of discontinued operations (371,613) 459,794
Net cash used in operating activities (7,678,730) (17,713,547)
Cash flows provided by (used in) investing activities:    
Purchase of property and equipment (213,105) (1,422,002)
Purchase of Jamestown Regional Medical Center (634,721)
Proceeds from the sale of equipment under capital lease 710,403
Net cash used in investing activities of continuing operations (137,423) (1,422,002)
Net cash provided by investing activities of discontinued operations 800,000 929,465
Net cash provided by (used in) investing activities 662,577 (492,537)
Cash flows (used in) provided by financing activities:    
Proceeds from issuance of common stock and warrants 639,615
Proceeds from issuance of Series I-1 Preferred Stock 4,000,000
Financing fees (25,000)
Proceeds from issuance of related party notes payable and advances 3,312,348 4,765,000
Proceeds from issuance of debentures 9,000,000 15,742,500
Payments on related party notes payable and advances (3,972,348) (5,298,782)
Payments on capital lease obligations (1,316,929) (1,680,747)
Cash paid for fractional shares in connection with reverse stock split (47) (6,675)
Net cash provided by financing activities of continuing operations 7,023,024 18,135,911
Net cash provided by financing activities of discontinued operations
Net cash provided by financing activities 7,023,024 18,135,911
Net increase (decrease) in cash 6,870 (70,173)
Cash at beginning of period 70,173
Cash at end of period $ 6,870